K

[K @HollevoetKevin]

FYI. My @AntibodyEng365 webinar and live Q&A on #intramuscular and #intratumoral DNA-based #antibody therapy is now available for all:
https://t.co/hELhSq4jAE https://t.co/s7DieJBZjD

[K @HollevoetKevin]

Proud to be part of this select Digital Week series in April. Register for free to hear more about "DNA-based #Antibody Therapy: A Blueprint for Innovation". I'll provide an overview of the #antibodygenetranfer field & share exciting data generated @LeuvenU. Don't miss out! https://t.co/mqWQ3HZXYY

[ASGCT @ASGCTherapy]

Now available: Our Q4 2021 publication from ASGCT and @Pharma_Intell, the Gene, Cell, & RNA Therapy Landscape report! Find out what happened in the fourth quarter, including approval of a new #celltherapy & a new #RNAtherapy in the U.S.! https://t.co/NQT1gQb1Pq

[nature @Nature]

Seven technologies set to shake up science in 2022 https://t.co/k92SFPQoU9

[Eric Topol @EricTopol]

🆕 Our review of #AI for medicine, just published @NatureMedicine
https://t.co/OAoAGmErns
@pranavrajpurkar, Emma Chen, Oishi Banerjee

[K @HollevoetKevin]

@dbervoet “jonger”? Zo wordt het idd een kakafonie 🙃

[K @HollevoetKevin]

@capoenie Aha. I see. Haven’t followed up on that.

[K @HollevoetKevin]

@capoenie Data indeed starts to emerge, e.g. https://t.co/wcR4KUiN20

[K @HollevoetKevin]

@NicoCallewaert Fyi - interesting thread

[Trevor Bedford @trvrb]

With data that has emerged in the last week, I'm now 80-90% convinced that infections by the UK variant virus (Pangolin lineage B.1.1.7, @nextstrain clade 20B/501Y.V1) result in, on average, more onward infections, ie are more transmissible. 1/10
https://t.co/g8HKduGvqW

[K @HollevoetKevin]

New publication by our #AntibodyGeneTransfer Program @KU_Leuven now online:“#Electroporation outperforms in vivo-jetPEI for #intratumoral DNA-based reporter gene transfer” @SciReports https://t.co/VWWSjCDdKK A brief but important report for the field! #genetherapy #transfection

[K @HollevoetKevin]

Now online: Paper from the #AntibodyGeneTransfer Program at @KU_Leuven, in collaboration with @AblynxNV, in @cgtnature: https://t.co/kBgVkRpUcF DNA-based delivery of #Nanobodies outperforms conventional protein administration, highlighting platform versatility & flexibility!

[K @HollevoetKevin]

@NicoCallewaert @InflamResCen @VIB_CMB @VIBLifeSciences @ugent “En door uw eigen lichaam gemaakt na vaccinatie... of anlichaamgentransfer” 😉

[K @HollevoetKevin]

@bart_lambrecht Fyi Bart, https://t.co/ynwWIAwtiO

[Meg Tirrell @megtirrell]

.⁦@latimes⁩ reports 2 patients with cytokine storm improved dramatically after treatment w Roche’s Actemra. Data from Regeneron’s first study w similar drug, Kevzara, due in next few weeks. #COVID19 https://t.co/2Ak4gEc9gs

[K @HollevoetKevin]

@AndyBiotech FYI https://t.co/mBmqFT0KeU

[Andy Biotech @AndyBiotech]

Nice update from @CancerResearch on global immuno-oncology drug pipeline
https://t.co/CaRB68LSLn

- Total number of I/O drugs almost doubled from 2030 to 3876 in two years
- Cell therapy tripled from 405 to 1202
- New targets increased 78% from 205 to 468

[Knack @Knack]

KUL-onderzoekers laten schapen antilichamen produceren met gentherapie https://t.co/n9RwfleQkg

[De Tijd @tijd]

Uw lichaam wordt een medicijnfabriek https://t.co/tbKg0Cmx6c

[KU Leuven @KU_Leuven]

Onderzoekers zijn erin geslaagd om schapen zelf antilichamen te laten produceren met behulp van een DNA-injectie. 💉 Het #onderzoek is een belangrijke doorbraak voor de behandeling van o.a. kanker en de griep. 👇 https://t.co/Yy5NPggPjC

[K @HollevoetKevin]

#BadBlood, a mustread for entrepreneurs, board members, investors & anyone aspiring a life sciences career. The detailed takedown of the rise and fall of #Theranos is just mindblowing. A powerful reminder of the need for solid science, corporate governance & due dilligence

[K @HollevoetKevin]

@HowardSchlauch Yes, I addressed all those topics in https://t.co/5UdputqlGq

[K @HollevoetKevin]

An exciting start of the year for antibody gene transfer. In a timespan of less than 30 days, 2 PhI trials on nucleotide-based antibody delivery have been announced. Both @InovioPharma (DNA) and @moderna_tx (mRNA) are pursuing expression of mAbs against #infectiousdiseases

[Lisa Jarvis @lisamjarvis]

FDA expanding cell & gene therapy review group. Agency says by '20, will have >200 cell or gene therapy INDs per year, adding to >800 active INDs on file. By 2025, "we predict that the FDA will be approving 10 to 20 cell and gene therapy products a year." https://t.co/juBjATLus5